
Pfizer and Janssen have decided to drop their investigational Alzheimer’s drug bapineuzumab after it failed a second late-stage study. The …

Pfizer and Janssen’s investigational Alzheimer’s drug bapineuzumab is no better than placebo, according to a new study. The Phase III …

Despite many years of relentless research efforts, Alzheimer’s disease, the most common form of dementia, remains impossible to cure. According …

